Press Room

News / Jul 14, 2022

ɫAV releases its 4th Sustainability Report

The sustainability report covers the fiscal years 2019 and 2020

ɫAV sustainability report 2019-2020 cover

The ispublished under the title “Elements of the future. For tomorrow and beyond, no matter what.”

This is the fourth Sustainability Report published by ɫAV and is intended to demonstrate our accountability to our stakeholders by communicating the company's progress on Environmental, Social and Governance (ESG) topics. The Report also reflects our alignment to the United Nations Sustainable Development Goals (UN SDGs).

The report has been prepared in line with the Global Reporting Initiative Standards content and quality principles, to ensure information accuracy, clarity and reliability. These standards enable greater transparency and accountability of organizations, by enhancing global comparability and quality of information around ESG performance. The information covers all our owned manufacturing and research facilities worldwide and the data presented is global.

As a company, we want to manufacture and deliver medicines of the highest quality to the patients aligned with our commitment to operating a sustainable business. We have as reference the highest standards of safety and environmental performance, staffed by an engaged and diverse workforce.

Being “In it for life” means that we are committed to protecting our people, our communities, our partners and the environment around us.

Find more about Sustainability at ɫAV

Also in the Press Room

See All

Lisbon, Portugal – ɫAV, the specialist integrated pharma CDMO and leader in spray drying and particle engineering, today announced its commitment to setting Science-Based Targets (SBTs) in line with the Paris Agreement. This ambitious step underscores the company’s dedication to addressing climate change and driving sustainability across its operations. By committing to SBTs, ɫAV joins a growing number of businesses taking concrete actions to reduce greenhouse gas emissions. This initiative aligns with the company’s broader sustainability strategy and reinforces its commitment to scientific excellence. “At ɫAV, we believe in science and in best practices. And this clearly applies to our sustainability agenda.”, said Jean-Luc Herbeaux, CEO of ɫAV. We made the decision to drive our GHG emissions down using a science-based target setting process, which will help us drive sustainability across our operations by laying out a clearly defined path to reduce emissions in line with the Paris Agreement goals. We believe that by setting ambitious targets and implementing concrete actions, we can make a positive impact on the planet while driving innovation and growth.” ɫAV will work closely with the Science Based Targets initiative (SBTi) to develop and validate its emission reduction targets. The company will provide regular updates on its progress towards achieving these goals. As part of its commitment to sustainability and transparency to stakeholders, the company will enhance its Ecovadis rating. Ecovadis, a leading sustainability assessment platform in the pharmaceutical industry, provides a comprehensive evaluation of a company’s environmental, social, and ethical performance, well aligned with ɫAV’s sustainability ambitions.  ɫAV remains dedicated to operating responsibly and contributing positively to society and the environment. The company will continue to implement sustainable practices across its operations and innovate to further improve its sustainability rating.   Learn more about Science Based-Targets  

News
ɫAV commitment to setting SBTs in line with the Paris Agreement

ɫAV Commits to Science-Based Targets for Greenhouse Gas (GHG) Emissions

Sep 09, 2024

The partnership with Higuchi forms part of ɫAV´s global expansion plans and marks a significant milestone in advancing ɫAV's presence in the Japanese market.    Under the terms of the agreement, Higuchi will promote ɫAV's pharmaceutical service business throughout Japan, using their extensive experience to enhance brand visibility and attract new clientele across the Japanese pharmaceutical landscape.  “This strategic collaboration underscores ɫAV's dedication to delivering innovative solutions and exceptional service to its customers,” said Yuken Kyoyama. “Our partnership with Higuchi will help to show customers in Japan how ɫAV can meet their needs.”    Learn more about our business in Japan and visit our website hovione.co.jp    

News
ɫAV proudly announces its collaborative venture with Higuchi.

ɫAV forges strategic partnership with Higuchi to further strengthen its presence in Japan

Jul 04, 2024

Following the creation of offices in Shanghai and Beijing, ɫAV is pleased to announce the launch of its new website in Mandarin. This dedicated platform will enhance ɫAV´s presence in China, offering tailored contents to better serve customers in this important market. The new site will provide comprehensive information about ɫAV´s products and services, ensuring that Chinese clients have easier access to the innovative solutions and support that ɫAV is renowned for worldwide.   “The launch of the ɫAV Chinese website underscores our commitment to customers in China,” said Ms. Jackie Liu, Country Head, China. “By delivering localized content and support, we aim to foster stronger partnerships and drive mutual growth in this market. Our team of experts is fully committed to understanding and addressing our clients´ unique challenges with agility and precision.” Visit us at www.hovione.com.cn    

News
ɫAV is closer to its customers with a new website in Mandarin

ɫAV launches new website for the Chinese Market

Jun 14, 2024

Also in Events

See All